CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
solifenacin succinate (VESIcare) +1 moredrug
Likely dose
solifenacin succinate (VESIcare) 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01018264
NCT01018264Phase 4Completed
CompareCT.gov

URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

University of South Florida·interventional·Posted Nov 23, 2009·Updated Nov 9, 2021

In Brief

A Phase 4 clinical trial evaluating solifenacin succinate (VESIcare) and placebo for Overactive Bladder in Parkinson's Disease. Completed, enrolled 23 participants across 3 sites.

Detailed Summary

This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder in Parkinson's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 23, 2009
Enrollment StartJan 1, 2010
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 16.6 years ago

Interventions

solifenacin succinate (VESIcare)drug

up to 10mg every day orally

placebodrug

placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day